<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601340</url>
  </required_header>
  <id_info>
    <org_study_id>HQP 1001-SCD-007</org_study_id>
    <nct_id>NCT01601340</nct_id>
  </id_info>
  <brief_title>Effects of HQK-1001 in Patients With Sickle Cell Disease</brief_title>
  <official_title>A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HemaQuest Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HemaQuest Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with
      sickle cell disease.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in % fetal hemoglobin</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and number of SCD pain crises and SCD-related complications</measure>
    <time_frame>Day 1 through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject reported daily pain scale scores and analgesic use</measure>
    <time_frame>7 consecutive days following clinic visits at Day 1, and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACIT Fatigue Scale results</measure>
    <time_frame>Day 1 and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by the frequency and severity of adverse events, and changes from baseline in vital signs, electrocardiogram (ECG) monitoring, and laboratory assessments</measure>
    <time_frame>Day 1 through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HQK-1001 pharmacokinetic parameters</measure>
    <time_frame>1 hour prior to, and 2 hours following morning dose on Weeks 12, 24 and 48</time_frame>
    <description>A subset of subjects (7) will undergo sampling for detailed analysis of pharmacokinetic parameters (AUC, Cmax) with samples taken pre-dose, and 1, 2, 4, 8, and 10 hours after the morning dose at Week 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Sickle Cell Anemia</condition>
  <condition>Sickle Cell Disorders</condition>
  <condition>Hemoglobin S Disease</condition>
  <condition>Sickling Disorder Due to Hemoglobin S</condition>
  <arm_group>
    <arm_group_label>HQK-1001</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HQK-1001</intervention_name>
    <description>HQK-1001 tablets, twice daily for 48 weeks</description>
    <arm_group_label>HQK-1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, twice daily for 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 12 and 60 years of age

          -  Diagnosis of SCD, type Hb SS or Hb S-B0 Thalassemia

          -  At least 1 episode of SCD pain crisis, acute chest syndrome, other acute SCD
             complications, or leg ulcers in the 12 months prior to screening

          -  Not being treated with Hydroxyurea (HU); if HU treatment has been previously
             administered and then discontinued, at least 3 months must have elapsed since last
             dose of HU

          -  If subject has been transfused in the 3 months prior to screening, then Hb A level &lt;
             20% at screening

          -  Baseline Hb F level obtained within 14 days prior to randomization

          -  Able to swallow tablets

          -  Able and willing to give informed consent and/or assent

          -  If subject is a woman of child-bearing potential (WCBP), she must have a negative
             serum pregnancy test within 14 days of first dose of HQK-1001 and a negative urine
             pregnancy test prior to dosing on Day 1

          -  If a subject is a WCBP, she must agree to use an effective form of contraception
             starting at screening and for one month after HQK-1001 discontinuation

          -  Sexually active male subjects who have not had a vasectomy must agree to use latex
             condoms with WCBP partners or ensure that their partner(s) use an effective form of
             contraception starting at screening and for one month after HQK-1001 discontinuation.

        Exclusion Criteria:

          -  Assigned to a regular transfusion program

          -  Use of erythropoiesis stimulating agents within 90 days prior to screening

          -  An SCD pain crisis or SCD-related acute complication within 3 weeks prior to
             randomization

          -  More than 5 SCD pain crisis or SCD-related acute complications within 12 months prior
             to screening

          -  Pulmonary hypertension requiring therapy

          -  ALT or AST &gt; 3x ULN

          -  Serum creatinine &gt; 1.5x ULN

          -  Serum amylase levels &gt; 1.5x ULN

          -  Serum lipase level &gt; 1.5x ULN

          -  A serious, concurrent illness that would limit ability to complete or comply with the
             study requirements

          -  An acute illness (e.g., febrile, GI, respiratory) within 72 hours prior to screening

          -  History of syncope, clinically significant dysrhythmias or resuscitation from sudden
             death due to SCD-related complication

          -  Symptomatic peptic ulcer, hiatus hernia, or gastroesophageal reflux disease (GERD)

          -  History of pancreatitis

          -  Chronic opiate use, which, in the view of the investigator, could confound evaluation
             of an investigational drug

          -  Current abuse of alcohol or drugs

          -  Use of another investigational agent within 4 weeks or 5 half-lives, whichever is
             longer, prior to screening

          -  Currently pregnant or breast feeding a child

          -  Known infection with HIV-1

          -  Infection with hepatitis B or hepatitis C, such that subjects are currently on
             anti-viral therapy or will be placed on therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Ghalie, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>HemaQuest Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617-2238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center - Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth Univeristy - Center on Health Disparities</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abu El Reesh Pediatric University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ain Sham University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the West Indies</name>
      <address>
        <city>Mona, Kingston 7</city>
        <country>Jamaica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chronic Care Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rafik Hariri University Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Egypt</country>
    <country>Jamaica</country>
    <country>Lebanon</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Sickle Cell Trait</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

